雾化吸入布地奈德联合特布他林对哮喘患儿肺功能的影响  

Effect of aerosol inhalation of budesonide combined with terbutaline on lung function in children with asthma

作　　者：卢鹏程[1] 曾镇钟 张佳妮 林静[1] 张灿煌 汪勇芬[1] LU Peng-cheng;ZENG Zhen-zhong;ZHANG Jia-ni;LIN Jing;ZHANG Can-huang;WANG Yong-fen(Department of Pediatrics,2nd Affiliated Hospital,Fujian Medical University,Quanzhou 362000,Fujian Province,China)

机构地区：[1]福建医科大学附属第二医院儿科,福建泉州362000

出　　处：《中国临床药理学杂志》2022年第5期387-390,共4页The Chinese Journal of Clinical Pharmacology

基　　金：福建省医学创新课题基金资助项目(2017-CXB-53)。

摘　　要：目的观察雾化吸入布地奈德联合特布他林对哮喘患儿肺功能及卵泡抑素样蛋白1(FSTL1)表达的影响。方法将90例哮喘患儿按照随机数字表法分为试验组与对照组,各45例。对照组给予雾化吸入布地奈德,每次1 mg,每次15 min,每天2次,连续治疗7 d;试验组在对照组的基础上使用空气压缩泵雾化吸入硫酸特布他林吸入粉雾剂,体重≤20 kg,每次2.5 mg;体重>20 kg,每次5mg。治疗前、治疗1 d、治疗7 d时,比较2组的肺功能[第1秒用力呼气容积(FEV_(1))、肺活量(FVC)]及外周血、肺泡灌洗液FSTL1表达;治疗期间,比较2组临床症状缓解时间、药物不良反应发生情况。结果治疗1,7 d,2组FEV_(1)、FVC水平均较治疗前升高,外周血、肺泡灌洗液FSTL1水平均较治疗前降低,且试验组治疗后各时点FEV_(1)、FVC水平均高于对照组,外周血、肺泡灌洗液FSTL1水平均低于对照组(P<0.05)。试验组咳嗽缓解时间、喘息缓解时间、胸闷缓解时间分别为(4.42±1.06),(4.28±0.98),(3.83±0.65) d,分别短于对照组的(5.24±0.98),(5.00±0.90),(4.35±0.80) d(P<0.05)。试验组药物不良反应发生率为12.50%,对照组为7.50%,差异无统计学意义(P>0.05)。结论在雾化吸入布地奈德基础上联合特布他林治疗哮喘,更利于改善患儿肺功能,患儿临床症状更好更快缓解,同时有利于下调患儿FSTL1水平,且不增加药物不良反应发生率,联合用药安全可靠。Objective To investigate the effect of aerosol inhalation of budesonide combined with terbutaline on lung function and follistatinlike protein 1 (FSTL1) expression in children with asthma.Methods Ninety children with asthma were divided into treatment group and control group according to random number table method,with 45 cases in each group.Control group was given aerosol inhalation of budesonide,1 mg a time,15 min a time,twice a day,for 7 d of continuous treatment;On the basis of control group,treatment group was given air compression pump aerosol inhalation of terbutaline sulfate powder for inhalation,body weight≤20 kg,2.5 mg a time;weight>20 kg,5 mg a time,for 7 d of continuous treatment.Before treatment,and 1,7 d of treatment,the pulmonary function[forced expiratory volume in one second (FEV_(1)),forced vital capacity (FVC)],FSTL1 expression in peripheral blood and alveolar lavage fluid were detected and compared between two groups.The relief time of clinical symptoms and the occurrence of adverse reactions in two groups were recorded and compared during treatment.Results At 1 d and 7 d of treatment,the levels of FEV_(1) and FVC in both groups were higher than those before treatment,the levels of FSTL1 in peripheral blood and alveolar lavage fluid were lower than those before treatment,and the levels of FEV_(1)and FVC in treatment group at each time point after treatment were higher than those in control group,and the levels of FSTL1 in peripheral blood and alveolar lavage fluid in treatment group were lower than those in control group (P<0.05).The average cough relief time,wheezing relief time and chest tightness relief time in treatment group were (4.42±1.06),(4.28±0.98) and (3.83±0.65) d,shorter than those in control group,which were (5.24±0.98),(5.00±0.90),(4.35±0.80) d (P<0.05).The incidence of adverse drug reactions in treatment group and control group were 12.50%,7.50%,there was no statistical significant difference between the two groups (P>0.05).Conclusion On the basis of aerosol inhalation

关 键 词：哮喘 布地奈德 特布他林 肺功能 卵泡抑素样蛋白1 

分 类 号：R972[医药卫生—药品]